Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials
| العنوان: | Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials |
|---|---|
| المؤلفون: | Sydney Akapame, Jennifer Cai, Linda M. Delahanty, Shana Traina, April Slee |
| المصدر: | The Patient |
| بيانات النشر: | Springer Science and Business Media LLC, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, 030209 endocrinology & metabolism, Placebo, law.invention, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Randomized controlled trial, law, Internal medicine, Humans, Hypoglycemic Agents, Medicine, Patient Reported Outcome Measures, Original Research Article, 030212 general & internal medicine, Canagliflozin, Aged, Randomized Controlled Trials as Topic, business.industry, Sitagliptin Phosphate, Type 2 Diabetes Mellitus, Odds ratio, Middle Aged, Placebo Effect, Clinical trial, Diabetes Mellitus, Type 2, Sitagliptin, Quality of Life, Female, business, medicine.drug |
| الوصف: | Background Evidence from patient-reported outcomes in clinical trials may explain health-related behaviors observed in the real world. Objective The purpose of this analysis was to evaluate the effect of treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with placebo or sitagliptin on health-related quality-of-life outcomes in participants with type 2 diabetes mellitus from the clinical development program. Methods Patient-reported outcomes data from four randomized controlled trials of canagliflozin (n = 2536) were pooled and analyzed to evaluate participants’ interest in continuing study medication; satisfaction with weight; and physical, mental, and emotional health after 26–52 weeks of treatment with canagliflozin vs. placebo or sitagliptin. Results Upon trial completion, participants treated with canagliflozin were more likely to express interest in continuing study medication than participants treated with placebo or sitagliptin [odds ratio (95% confidence interval) of 1.54 (1.19–1.99); p = 0.001]. Those treated with canagliflozin were also more likely to be satisfied with their weight and report favorable outcomes (score improvement or maintenance of good scores) related to physical and emotional health. Conclusions The results of this pooled analysis suggest that people with type 2 diabetes mellitus treated with canagliflozin generally had positive experiences with treatment and improvements in health-related quality of life. Future research is needed to determine if these improvements result in improved type 2 diabetes mellitus management and treatment adherence. ClinicalTrials.gov identifiers NCT01106625, NCT01106677, NCT01137812, NCT02025907. Electronic supplementary material The online version of this article (10.1007/s40271-017-0290-4) contains supplementary material, which is available to authorized users. |
| تدمد: | 1178-1661 1178-1653 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e489f177d60221782253d905f1172905Test https://doi.org/10.1007/s40271-017-0290-4Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e489f177d60221782253d905f1172905 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 11781661 11781653 |
|---|